RHBC
AMED

R.H. Bluestein & Co’s Amedisys AMED Stock Holding History

R.H. Bluestein & Co’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,100
Closed -$269K – 421
2021
Q2 		$269K Hold
1,100
– – 0.01% 348
2021
Q1 		$291K Sell
1,100
-250
-19% -$70.5K 0.01% 320
2020
Q4 		$396K Buy
1,350
+50
+4% +$12.8K 0.02% 230
2020
Q3 		$307K Buy
+1,300
New +$296K 0.02% 244

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

R.H. Bluestein & Co's AMED Position: Q3 2021 in Review

R.H. Bluestein & Co sold out of Amedisys (AMED) in Q3 2021, closing a stake of 1,100 shares — an estimated $269K sold.

R.H. Bluestein & Co first reported a position in AMED in Q3 2020 and held it in 4 quarters. The position peaked at $396K in Q4 2020. 351 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

  • R.H. Bluestein & Co reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
  • R.H. Bluestein & Co sold 1,100 Amedisys shares in Q3 2021, an estimated $269K.
  • R.H. Bluestein & Co first reported a position in Amedisys in Q3 2020 and held it in 4 quarters.
  • R.H. Bluestein & Co's Amedisys position peaked at $396K in Q4 2020.
  • 351 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on R.H. Bluestein & Co's 13F filing for Q3 2021, filed 12 Nov 2021.